Enhancing anti-cancer activity of erlotinib by antibody conjugated nanofibrin - In vitro studies on lung adenocarcinoma cell lines

Abstract Fabrication of nanomaterials for active targeting of therapeutics to the site of tumour is quite challenging in treating most types of cancer. Herein, we report the synthesis of antibody linked fibrin nanoparticles for the treatment of non-small cell lung cancer (NSCLC). Wet precipitation and EDC/NHS activation methods were employed to prepare the positively charged spherical shaped antibody linked fibrin nanoparticles (BV-ERB-FN) with size of 79 nm. The formulated nanoparticles significantly reduced the viability and proliferation of A549 lung adenocarcinoma cells with an IC 50 concentration of 0.84 μM/mL. BV-ERB-FN treated cells showed efficient cell cycle arrest with gradual decrease in G0/G1 phase and steady increase in sub-G0/G1 phase, thereby leading to the effective killing of cancer cells under in vitro conditions.